These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 35860245)
21. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial. Grieco DL; Menga LS; Cesarano M; Rosà T; Spadaro S; Bitondo MM; Montomoli J; Falò G; Tonetti T; Cutuli SL; Pintaudi G; Tanzarella ES; Piervincenzi E; Bongiovanni F; Dell'Anna AM; Delle Cese L; Berardi C; Carelli S; Bocci MG; Montini L; Bello G; Natalini D; De Pascale G; Velardo M; Volta CA; Ranieri VM; Conti G; Maggiore SM; Antonelli M; JAMA; 2021 May; 325(17):1731-1743. PubMed ID: 33764378 [TBL] [Abstract][Full Text] [Related]
22. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077 [TBL] [Abstract][Full Text] [Related]
23. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Xu X; Jiang W; Chen L; Xu Z; Zhang Q; Zhu M; Ye P; Li H; Yu L; Zhou X; Zhou C; Chen X; Zheng X; Xu K; Cai H; Zheng S; Jiang W; Wu X; Li D; Chen L; Luo Q; Wang Y; Qu J; Li Y; Zheng W; Jiang Y; Tang L; Xiang C; Li L Clin Transl Med; 2021 Feb; 11(2):e297. PubMed ID: 33634996 [TBL] [Abstract][Full Text] [Related]
25. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS. Häberle H; Magunia H; Lang P; Gloeckner H; Körner A; Koeppen M; Backchoul T; Malek N; Handgretinger R; Rosenberger P; Mirakaj V J Intensive Care Med; 2021 Jun; 36(6):681-688. PubMed ID: 33663244 [TBL] [Abstract][Full Text] [Related]
27. Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome? Hamdan H; Hashmi SK; Lazarus H; Gale RP; Qu W; El Fakih R Blood Rev; 2021 Mar; 46():100742. PubMed ID: 32854985 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study. Grumet M; Sherman J; Dorf BS Stem Cells Transl Med; 2022 Nov; 11(11):1103-1112. PubMed ID: 36181766 [TBL] [Abstract][Full Text] [Related]
29. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review. Sadeghi B; Ringdén O; Gustafsson B; Castegren M Front Immunol; 2022; 13():963445. PubMed ID: 36426365 [TBL] [Abstract][Full Text] [Related]
30. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery. Couto PS; Al-Arawe N; Filgueiras IS; Fonseca DLM; Hinterseher I; Catar RA; Chinnadurai R; Bersenev A; Cabral-Marques O; Moll G; Verter F Front Immunol; 2023; 14():1200180. PubMed ID: 37415976 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the efficacy of equivalent doses of dexamethasone, methylprednisolone, and hydrocortisone for treatment of COVID-19-related acute respiratory distress syndrome: a prospective three-arm randomized clinical trial. Taher A; Lashkari M; Keramat F; Hashemi SH; Sedighi L; Poorolajal J; Mehrpooya M Wien Med Wochenschr; 2023 Apr; 173(5-6):140-151. PubMed ID: 36624180 [TBL] [Abstract][Full Text] [Related]
32. Safety and Effectiveness of Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19 Complications. Atluri S; Manocha V; Boddu N; Bhati S; Syed Z; Diwan S; Manchikanti L Pain Physician; 2020 Aug; 23(4S):S391-S420. PubMed ID: 32942796 [TBL] [Abstract][Full Text] [Related]
33. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Rebelatto CLK; Senegaglia AC; Franck CL; Daga DR; Shigunov P; Stimamiglio MA; Marsaro DB; Schaidt B; Micosky A; de Azambuja AP; Leitão CA; Petterle RR; Jamur VR; Vaz IM; Mallmann AP; Carraro Junior H; Ditzel E; Brofman PRS; Correa A Stem Cell Res Ther; 2022 Mar; 13(1):122. PubMed ID: 35313959 [TBL] [Abstract][Full Text] [Related]
34. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial". Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395 [TBL] [Abstract][Full Text] [Related]
35. Potential application of mesenchymal stromal cells as a new therapeutic approach in acute respiratory distress syndrome and pulmonary fibrosis. Gazzaniga G; Voltini M; Carletti A; Lenta E; Meloni F; Briganti DF; Avanzini MA; Comoli P; Belliato M Respir Res; 2024 Apr; 25(1):170. PubMed ID: 38637860 [TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II. Fathi-Kazerooni M; Fattah-Ghazi S; Darzi M; Makarem J; Nasiri R; Salahshour F; Dehghan-Manshadi SA; Kazemnejad S Stem Cell Res Ther; 2022 Mar; 13(1):96. PubMed ID: 35255966 [TBL] [Abstract][Full Text] [Related]
37. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial. Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A; Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496 [TBL] [Abstract][Full Text] [Related]
39. Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial. Declercq J; Bosteels C; Van Damme K; De Leeuw E; Maes B; Vandecauter A; Vermeersch S; Delporte A; Demeyere B; Vuylsteke M; Lalla M; Smart T; Detalle L; Bouw R; Streffer J; Degeeter T; Vergotte M; Guisez T; Van Braeckel E; Van Der Straeten C; Lambrecht BN Trials; 2020 Nov; 21(1):934. PubMed ID: 33213529 [TBL] [Abstract][Full Text] [Related]
40. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial. Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]